$33.20
-0.15 (-0.45%)
Open$33.45
Previous Close$33.35
Day High$33.63
Day Low$32.24
52W High$43.85
52W Low$6.74
Volume—
Avg Volume294.9K
Market Cap481.87M
P/E Ratio—
EPS$-16.35
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-72.3% upside
Current
$33.20
$33.20
Target
$9.21
$9.21
$5.69
$9.21 avg
$10.08
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 196.13M | 170.88M | 26.00M |
| Net Income | -365,694,678 | -286,744,389 | 1.01M |
| Profit Margin | -186.5% | -177.1% | 3.9% |
| EBITDA | -289,062,481 | -239,248,437 | 1.64M |
| Free Cash Flow | — | — | 646.8K |
| Rev Growth | +14.8% | +14.8% | +22.0% |
| Debt/Equity | — | — | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |